Sleep Disorders

Statistically significant worsening on the Epworth Sleepiness Scale was observed in patients randomized to placebo compared to participants who received JZP-258.

Here's what is coming soon to NeurologyLive.

The rate of maternal clinical insomnia increased from 11% pre-pandemic to 23% during the COVID-19 pandemic.

Neurology News Network for the week ending October 17, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 16, 2020.

The recently approved oral solution, known as JZP-28 (Xywav), was associated with clinically meaningful improvements in Epworth Sleepiness Scale, Patient Global Impression of Change, and Idiopathic Hypersomnia Severity Scale scores.

The drug, marketed as Wakix, was previously approved for the treatment of excessive daytime sleepiness in adults with narcolepsy.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 9, 2020.

The initiative, funded by Jazz, will include educational multimedia content such as a series of podcasts with expert interviews discussing sleep and related disorders.

Julio J. Fernandez-Mendoza, PhD, a clinician-scientist at Penn State Hershey Sleep Research & Treatment Center, of Penn State Health, spoke to the implications of a recent study he and colleagues conducted.

Neurology News Network for the week ending October 2, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 2, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 25, 2020.

The findings suggest that this insomnia phenotype is a more biologically severe form of the disorder associated with cardiovascular, cerebrovascular, and neurocognitive morbidity.

Neurology News Network for the week ending September 12, 2020.

Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, shares details from her study on the psychosocial impact on physicians and her first-hand experience.

Neurology News Network for the week ending September 5, 2020.

Despite previous literature documenting cardiovascular disease comorbidity in patients with narcolepsy, pitolisant treatment did not demonstrate any cardiac safety signals.

The findings support the integration of sleep assessments into routine developmental screenings in school and primary care settings.

The FDA-approved agent showed significant impact in decreasing standard deviation of lateral position, a measure used to assess driving performance.

Pooled data from 2 clinical trials of the H3-receptor antagonist/inverse agonist show it improved cataplexy and excessive daytime sleepiness in patients with narcolepsy who were most hampered by symptoms.

Already FDA approved for the treatment of insomnia in adults, lemborexant’s ability to improve sleep outcomes in the elderly was highlighted in a study presented at SLEEP 2020.

Managing narcolepsy via behavioral strategies to improve excessive daytime sleepiness may be challenging but has shown some added efficacy when combined with pharmacological treatment for EDS.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 28, 2020.